Page 883 - Hematology_ Basic Principles and Practice ( PDFDrive )
P. 883
766 Part VII Hematologic Malignancies
With recurrent genetic abnormalities AML with t (8;21)(q22;q22.1);RUNX1-RUNX1T1 AML with inv(16)(p13.1q22) or t(16;16) (p13.1;q22);CBFB-MYH11 AML with t(9;11)(p21.3;q23.3);MLLT3-KMT2A AML with t(6;9)(p23;q34.1);DEK-NUP214 AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM AML (megakaryoblastic) with t(1;22) (p13.3;q13.3);RBM15-MKL1 Provisional entity: AML with BCR-ABL1 AML with mutated NPM1 AML with biallelic mutations of CEBPA Provi
WHO (2016) APL with PML-RARA AML, NOS AML with maturation Myeloid sarcoma
With recurrent genetic abnormalities With inv(16)/t(16;16)(p13.1;q22) With t(15;17)(q22;q12) With inv(3)/t(3;3)(q21;q26.2) With mutated NPM1 (provisional) With mutated CEBPA (provisional) With myelodysplasia related changes Previous history of MDS MDS-related cytogenetic abnormalities Therapy-related myeloid neoplasms With minimal differentiation Myelomonocytic leukemia Acute megakaryoblastic leukemia Acute basophilic leukemia Acute panmyelo
WHO (2008) With t(8;21)(q22;q22) With t(9;11)(p22;q23) With t(6;9)(p23;q34) With t(1;22)(p13;q13) Multilineage dysplasia t-AML/t-MDS (t-MN) Not otherwise specified Without maturation With maturation Monoblastic leukemia Monocytic leukemia Erythroleukemia Erythroid myeloid type Pure erythroid Myeloid sarcoma
Classification Schemes for the Acute Myelogenous Leukemias
WHO (2001) Genetic t(8;21) t(inv(16)/t(16;16) t(15;17) t(v;11q23) AML with dysplasia therapy related AML Etoposide Cytotoxic or radiation Not otherwise specified With minimal differentiation Without maturation With maturation Myelomonocytic leukemia Monoblastic leukemia Monocytic leukemia Erythroleukemia Erythroid myeloid type Pure erythroid Megakaryoblastic AML, Acute myeloid leukemia; AMML, acute myelomonocytic leukemia; APL, acut
Cytogenetic Favorable t(8;21) inv(16)/t(16;16) t(15;17) Intermediate Normal +8 t(v;11q23) del(7q) +21 +22 Other Adverse del(5q) -5 -7 Complex abn (3q)
French–American–British (FAB, M0: AML with minimal differentiation M1: AML without maturation M2: AML with maturation M3v: microgranular variant M4eo: AMML with abnormal M5A: acute monoblastic M5B: acute monocytic M6: erythroleukemia M7: acute megakaryoblastic
TABLE 55.4 1985) M3: APL M4: AMML eosinophils leukemia Leukemia leukemia
